Pharma M&A falls in 2012; Texas cancer agency under investigation;

Conversation on Twitter :

 @FierceBiotech: Nuron acquires Pfizer's meningitis vaccine. Story | Follow @FierceBiotech

@JohnCFierce: What does Lilly have? A signal, unconfirmed, that solanezumab works in mild Alzheimer's. See you in 3-4 years, alongside much competition. | Follow @JohnCFierce

@RyanFierce: Gilead wants a piece of the big oncology pie, as it showed with the Yale deal last year. YM could get it there sooner. Report | Follow @RyanMFierce

> Drug company mergers and acquisitions have fallen 35% this year. Report

> Galderma Pharma is buying fellow dermatology specialist Spirig Pharma. Release

> GlaxoSmithKline ($GSK) researcher Zhong Zhong used models of Alzheimer's disease made with induced pluripotent stem cells in high-throughput screening. Release

Pharma News

@FiercePharma: Sanofi, Merck, others said to be eyeing Bausch buyout. Story | Follow @FiercePharma

> Pharma M&A takes nosedive, except in China. Report

> French drug exec charged with manslaughter over drug safety. News

> Levin lays out 4-year plan to turn Teva into a brand. Article

Medical Device News

 @FierceMedDev: Medtronic facing federal suit from 'exploited' patients. Story | Follow @FierceMedDev

@MarkHFierce: Cerapedics pulled in a $19M Series C for its bone graft development work. New investors include MedImmune. More | Follow @MarkHFierce

 @DamianFierce: Welch Allyn isn't done reorganizing. After announcing plans to cut 275 jobs, it's moving its Euro HQ. Article | Follow @DamianFierce

> Myriad, Sanofi to team on diabetes biomarker Dx discovery work. Item

> BG Medicine gains CE mark for cardiovascular Dx. News

Drug Delivery News

> Eleven's lead topical eye drug completes PhIa, enters PhIb trials. Report

> Silver bullet targets antibiotics to deep infections. News

> Porcupine quills point to less painful shots. Story

> Sirtex, SingHealth develop stealth cancer treatments. Article

> Alnylam plans clinical trials for RNAi therapeutic. More

And Finally… State prosecutors have mounted a probe of a Texas agency that funds cancer research. Its executive director is resigning. Article

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.